12月16日 - ** 券商Evercore ISI开始对胰岛素设备制造商Insulet PODD.O进行跟踪评级，评级为 "跑赢大盘"，目标价为370美元。
** 与该股上次收盘价相比，PT上涨了27%。
** 券商称，Insulet有望继续保持胰岛素泵市场的领先地位
** 预计对其无管式技术的需求将持续增长数年
** Evercore ISI 认为，Insulet 的无管、一次性 Omnipod 设计、通过零售药店的广泛供应以及占据 65% 以上的胰岛素自动输送新用户，都支撑着该公司的增长前景。
** 我们认为，在规模庞大、渗透率较低的泵市场中，将会出现多个赢家。然而，我们认为 PODD 仍将是市场领导者，因为新进入者将面临很高的进入壁垒。
** 截至上一交易日收盘，PODD 股价年累计上涨 11.7
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.